| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atrial Fibrillation | 169 | 2025 | 832 | 24.750 |
Why?
|
| Stroke | 48 | 2024 | 1189 | 6.010 |
Why?
|
| Anticoagulants | 39 | 2024 | 494 | 5.420 |
Why?
|
| Frailty | 12 | 2024 | 130 | 4.800 |
Why?
|
| Electrocardiography | 41 | 2025 | 554 | 4.450 |
Why?
|
| Heart Failure | 45 | 2023 | 912 | 4.110 |
Why?
|
| Aged | 193 | 2025 | 14335 | 3.930 |
Why?
|
| Male | 221 | 2025 | 29706 | 3.210 |
Why?
|
| Acute Coronary Syndrome | 22 | 2021 | 251 | 3.020 |
Why?
|
| Female | 222 | 2025 | 32654 | 3.020 |
Why?
|
| Risk Factors | 100 | 2025 | 5324 | 2.980 |
Why?
|
| Humans | 316 | 2025 | 63001 | 2.960 |
Why?
|
| Risk Assessment | 44 | 2025 | 2065 | 2.660 |
Why?
|
| Middle Aged | 150 | 2025 | 17489 | 2.610 |
Why?
|
| Myocardial Infarction | 29 | 2018 | 905 | 2.540 |
Why?
|
| Photoplethysmography | 17 | 2025 | 35 | 2.480 |
Why?
|
| Heart Rate | 24 | 2025 | 318 | 2.400 |
Why?
|
| Patient Readmission | 9 | 2024 | 430 | 2.270 |
Why?
|
| Patient Discharge | 16 | 2024 | 511 | 2.260 |
Why?
|
| Wearable Electronic Devices | 13 | 2025 | 68 | 2.160 |
Why?
|
| Aged, 80 and over | 75 | 2025 | 5432 | 2.130 |
Why?
|
| Practice Patterns, Physicians' | 14 | 2020 | 709 | 2.110 |
Why?
|
| Heart Atria | 14 | 2021 | 137 | 2.100 |
Why?
|
| Cardiovascular Diseases | 14 | 2024 | 832 | 2.080 |
Why?
|
| Quality of Life | 18 | 2023 | 1223 | 2.040 |
Why?
|
| Stroke Volume | 19 | 2021 | 330 | 1.980 |
Why?
|
| Prospective Studies | 46 | 2024 | 3272 | 1.960 |
Why?
|
| Smartphone | 5 | 2024 | 69 | 1.950 |
Why?
|
| MicroRNAs | 8 | 2020 | 680 | 1.920 |
Why?
|
| Hospitalization | 32 | 2024 | 1354 | 1.920 |
Why?
|
| Atrial Function, Left | 6 | 2020 | 32 | 1.890 |
Why?
|
| Prognosis | 45 | 2025 | 1738 | 1.890 |
Why?
|
| Hypertension | 14 | 2025 | 584 | 1.880 |
Why?
|
| Cognitive Dysfunction | 10 | 2025 | 330 | 1.830 |
Why?
|
| Geriatric Assessment | 8 | 2024 | 163 | 1.770 |
Why?
|
| Massachusetts | 46 | 2025 | 2071 | 1.750 |
Why?
|
| Exercise | 12 | 2025 | 939 | 1.740 |
Why?
|
| Electronic Health Records | 13 | 2024 | 361 | 1.730 |
Why?
|
| Cohort Studies | 41 | 2025 | 2554 | 1.710 |
Why?
|
| Ventricular Function, Left | 13 | 2021 | 269 | 1.710 |
Why?
|
| Incidence | 39 | 2024 | 1369 | 1.620 |
Why?
|
| Suprachiasmatic Nucleus | 3 | 2024 | 142 | 1.580 |
Why?
|
| Atrial Remodeling | 6 | 2020 | 17 | 1.570 |
Why?
|
| Mass Screening | 14 | 2025 | 692 | 1.560 |
Why?
|
| Longitudinal Studies | 24 | 2024 | 1252 | 1.520 |
Why?
|
| Ventricular Premature Complexes | 7 | 2022 | 21 | 1.500 |
Why?
|
| Mobile Applications | 9 | 2025 | 135 | 1.460 |
Why?
|
| Circadian Rhythm | 3 | 2024 | 381 | 1.440 |
Why?
|
| Age Factors | 28 | 2025 | 1549 | 1.420 |
Why?
|
| Hemorrhage | 12 | 2022 | 266 | 1.420 |
Why?
|
| Administration, Oral | 12 | 2023 | 369 | 1.420 |
Why?
|
| Catheter Ablation | 5 | 2017 | 151 | 1.410 |
Why?
|
| Sepsis | 9 | 2022 | 285 | 1.370 |
Why?
|
| Algorithms | 27 | 2024 | 998 | 1.370 |
Why?
|
| Inpatients | 5 | 2018 | 302 | 1.320 |
Why?
|
| Echocardiography | 12 | 2020 | 499 | 1.300 |
Why?
|
| Point-of-Care Testing | 3 | 2024 | 43 | 1.290 |
Why?
|
| Cell Phone | 5 | 2019 | 44 | 1.270 |
Why?
|
| Monitoring, Physiologic | 7 | 2024 | 156 | 1.230 |
Why?
|
| Cognition | 9 | 2023 | 483 | 1.220 |
Why?
|
| Decision Support Techniques | 3 | 2020 | 195 | 1.160 |
Why?
|
| Prevalence | 23 | 2023 | 1371 | 1.140 |
Why?
|
| United States | 48 | 2025 | 7782 | 1.130 |
Why?
|
| Drug Utilization | 6 | 2020 | 209 | 1.110 |
Why?
|
| Cardiologists | 4 | 2023 | 28 | 1.100 |
Why?
|
| Registries | 11 | 2020 | 880 | 1.080 |
Why?
|
| Anti-Arrhythmia Agents | 5 | 2024 | 98 | 1.070 |
Why?
|
| Frail Elderly | 4 | 2024 | 108 | 1.040 |
Why?
|
| Machine Learning | 5 | 2024 | 174 | 1.040 |
Why?
|
| Factor Xa Inhibitors | 5 | 2020 | 35 | 1.030 |
Why?
|
| Ventricular Remodeling | 7 | 2020 | 83 | 1.030 |
Why?
|
| Time Factors | 33 | 2025 | 3752 | 1.030 |
Why?
|
| Sex Factors | 15 | 2024 | 971 | 1.010 |
Why?
|
| Adult | 63 | 2025 | 16722 | 0.990 |
Why?
|
| Hospital Mortality | 16 | 2019 | 867 | 0.980 |
Why?
|
| Follow-Up Studies | 28 | 2024 | 2452 | 0.960 |
Why?
|
| Blood Platelets | 3 | 2015 | 101 | 0.930 |
Why?
|
| Circadian Clocks | 2 | 2023 | 48 | 0.930 |
Why?
|
| Artificial Intelligence | 2 | 2024 | 178 | 0.910 |
Why?
|
| Blood Pressure | 11 | 2025 | 507 | 0.910 |
Why?
|
| Health Personnel | 6 | 2024 | 366 | 0.900 |
Why?
|
| Biological Specimen Banks | 1 | 2024 | 23 | 0.900 |
Why?
|
| Period Circadian Proteins | 1 | 2024 | 73 | 0.880 |
Why?
|
| Treatment Outcome | 34 | 2021 | 5630 | 0.880 |
Why?
|
| Retrospective Studies | 36 | 2022 | 6602 | 0.880 |
Why?
|
| Surveys and Questionnaires | 16 | 2024 | 2666 | 0.880 |
Why?
|
| Medicare | 8 | 2022 | 609 | 0.870 |
Why?
|
| Specimen Handling | 1 | 2024 | 62 | 0.870 |
Why?
|
| Georgia | 13 | 2022 | 87 | 0.840 |
Why?
|
| Electronics | 3 | 2023 | 35 | 0.840 |
Why?
|
| Electrocardiography, Ambulatory | 7 | 2025 | 44 | 0.830 |
Why?
|
| Biomarkers | 17 | 2024 | 1391 | 0.820 |
Why?
|
| Natriuretic Peptide, Brain | 4 | 2016 | 55 | 0.820 |
Why?
|
| Sensitivity and Specificity | 15 | 2024 | 1143 | 0.800 |
Why?
|
| Comorbidity | 18 | 2021 | 1117 | 0.790 |
Why?
|
| Counseling | 3 | 2019 | 362 | 0.770 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2025 | 718 | 0.770 |
Why?
|
| Cryptochromes | 1 | 2022 | 42 | 0.770 |
Why?
|
| Coronary Disease | 6 | 2019 | 246 | 0.760 |
Why?
|
| Signal Processing, Computer-Assisted | 9 | 2024 | 96 | 0.760 |
Why?
|
| Atrial Premature Complexes | 4 | 2021 | 13 | 0.750 |
Why?
|
| Patient Preference | 1 | 2022 | 84 | 0.750 |
Why?
|
| Cross-Sectional Studies | 16 | 2025 | 2562 | 0.730 |
Why?
|
| Anxiety | 6 | 2023 | 421 | 0.720 |
Why?
|
| Predictive Value of Tests | 15 | 2025 | 1080 | 0.710 |
Why?
|
| Atrial Flutter | 5 | 2020 | 23 | 0.710 |
Why?
|
| Cognition Disorders | 3 | 2017 | 216 | 0.710 |
Why?
|
| Self Report | 6 | 2023 | 375 | 0.710 |
Why?
|
| Obesity | 6 | 2024 | 1223 | 0.700 |
Why?
|
| Protein Transport | 1 | 2022 | 400 | 0.700 |
Why?
|
| Intensive Care Units | 4 | 2022 | 406 | 0.700 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2022 | 57 | 0.690 |
Why?
|
| Ventricular Dysfunction, Left | 6 | 2020 | 165 | 0.680 |
Why?
|
| Heart Rate Determination | 1 | 2020 | 2 | 0.680 |
Why?
|
| Pharmaceutical Services | 1 | 2020 | 33 | 0.670 |
Why?
|
| Drug Costs | 1 | 2020 | 56 | 0.670 |
Why?
|
| Rural Population | 2 | 2019 | 203 | 0.660 |
Why?
|
| Coronary Artery Disease | 4 | 2014 | 310 | 0.650 |
Why?
|
| Population Surveillance | 2 | 2018 | 205 | 0.640 |
Why?
|
| Proportional Hazards Models | 19 | 2019 | 727 | 0.640 |
Why?
|
| Patient Satisfaction | 3 | 2024 | 432 | 0.640 |
Why?
|
| Medical Order Entry Systems | 1 | 2020 | 42 | 0.640 |
Why?
|
| Electronic Mail | 1 | 2020 | 46 | 0.630 |
Why?
|
| Musculoskeletal Diseases | 1 | 2020 | 103 | 0.620 |
Why?
|
| Guideline Adherence | 3 | 2018 | 305 | 0.620 |
Why?
|
| Inappropriate Prescribing | 1 | 2020 | 66 | 0.620 |
Why?
|
| Reminder Systems | 1 | 2020 | 74 | 0.620 |
Why?
|
| Accountable Care Organizations | 1 | 2020 | 67 | 0.610 |
Why?
|
| C-Reactive Protein | 4 | 2014 | 166 | 0.610 |
Why?
|
| Thromboembolism | 2 | 2018 | 73 | 0.610 |
Why?
|
| Cardiovascular Agents | 4 | 2017 | 103 | 0.600 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2024 | 761 | 0.600 |
Why?
|
| Cigarette Smoking | 1 | 2019 | 57 | 0.590 |
Why?
|
| Osteoarthritis | 1 | 2020 | 140 | 0.590 |
Why?
|
| Heart Diseases | 3 | 2020 | 217 | 0.580 |
Why?
|
| Echocardiography, Doppler | 3 | 2018 | 133 | 0.580 |
Why?
|
| Genome-Wide Association Study | 7 | 2025 | 357 | 0.570 |
Why?
|
| Reproducibility of Results | 12 | 2023 | 1647 | 0.570 |
Why?
|
| Research Design | 7 | 2021 | 573 | 0.560 |
Why?
|
| Physicians, Primary Care | 1 | 2018 | 78 | 0.550 |
Why?
|
| Intracranial Hemorrhages | 3 | 2021 | 66 | 0.550 |
Why?
|
| Multivariate Analysis | 16 | 2017 | 932 | 0.550 |
Why?
|
| Patient Education as Topic | 4 | 2024 | 474 | 0.540 |
Why?
|
| Odds Ratio | 12 | 2021 | 765 | 0.540 |
Why?
|
| Transcriptome | 3 | 2018 | 387 | 0.530 |
Why?
|
| Cost of Illness | 2 | 2017 | 160 | 0.530 |
Why?
|
| Physicians | 1 | 2022 | 468 | 0.530 |
Why?
|
| Pulse Wave Analysis | 1 | 2016 | 14 | 0.510 |
Why?
|
| Feasibility Studies | 4 | 2024 | 567 | 0.510 |
Why?
|
| Vascular Stiffness | 1 | 2016 | 16 | 0.510 |
Why?
|
| Electric Countershock | 2 | 2018 | 101 | 0.510 |
Why?
|
| Mental Health | 1 | 2019 | 370 | 0.500 |
Why?
|
| Pulse | 1 | 2015 | 16 | 0.490 |
Why?
|
| Diabetes Complications | 4 | 2020 | 106 | 0.490 |
Why?
|
| Telemetry | 1 | 2015 | 19 | 0.490 |
Why?
|
| Pulmonary Veins | 1 | 2015 | 37 | 0.480 |
Why?
|
| Embolism | 1 | 2016 | 41 | 0.480 |
Why?
|
| Insurance Claim Review | 1 | 2015 | 73 | 0.480 |
Why?
|
| Glomerular Filtration Rate | 4 | 2013 | 113 | 0.480 |
Why?
|
| Defibrillators, Implantable | 4 | 2018 | 265 | 0.480 |
Why?
|
| Angiotensin Receptor Antagonists | 4 | 2017 | 65 | 0.480 |
Why?
|
| Recurrence | 8 | 2025 | 637 | 0.470 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2017 | 143 | 0.470 |
Why?
|
| Cardiology | 6 | 2021 | 167 | 0.470 |
Why?
|
| Telemedicine | 2 | 2021 | 320 | 0.460 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 3 | 2025 | 36 | 0.460 |
Why?
|
| Artifacts | 7 | 2024 | 124 | 0.460 |
Why?
|
| Quality Improvement | 2 | 2018 | 439 | 0.450 |
Why?
|
| Body Mass Index | 7 | 2024 | 859 | 0.450 |
Why?
|
| Logistic Models | 12 | 2021 | 1270 | 0.440 |
Why?
|
| Aging | 4 | 2020 | 743 | 0.440 |
Why?
|
| Fitness Trackers | 3 | 2025 | 20 | 0.430 |
Why?
|
| Diabetes Mellitus | 8 | 2019 | 535 | 0.430 |
Why?
|
| Smoking Cessation | 1 | 2019 | 549 | 0.430 |
Why?
|
| Dementia | 1 | 2017 | 258 | 0.430 |
Why?
|
| Disease Management | 1 | 2015 | 231 | 0.430 |
Why?
|
| Cardiac Electrophysiology | 2 | 2024 | 2 | 0.420 |
Why?
|
| Alcohol Drinking | 1 | 2016 | 314 | 0.420 |
Why?
|
| Genetic Variation | 5 | 2025 | 383 | 0.410 |
Why?
|
| Thrombosis | 1 | 2015 | 199 | 0.410 |
Why?
|
| Survival Rate | 11 | 2020 | 845 | 0.410 |
Why?
|
| Aftercare | 5 | 2021 | 76 | 0.400 |
Why?
|
| Gastrointestinal Stromal Tumors | 2 | 2011 | 20 | 0.400 |
Why?
|
| Long-Term Care | 4 | 2021 | 176 | 0.400 |
Why?
|
| Heart Arrest | 3 | 2016 | 170 | 0.400 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2020 | 149 | 0.390 |
Why?
|
| Computers, Handheld | 3 | 2025 | 38 | 0.390 |
Why?
|
| Brain Ischemia | 4 | 2019 | 415 | 0.390 |
Why?
|
| Pilot Projects | 5 | 2024 | 1004 | 0.390 |
Why?
|
| Point-of-Care Systems | 2 | 2024 | 129 | 0.390 |
Why?
|
| Qualitative Research | 4 | 2024 | 682 | 0.390 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2025 | 488 | 0.390 |
Why?
|
| Mortality | 5 | 2019 | 159 | 0.380 |
Why?
|
| Cancer Survivors | 2 | 2025 | 115 | 0.380 |
Why?
|
| Pharmacists | 3 | 2023 | 126 | 0.380 |
Why?
|
| Case-Control Studies | 10 | 2025 | 1117 | 0.380 |
Why?
|
| Survivors | 5 | 2019 | 169 | 0.370 |
Why?
|
| Interleukin-6 | 1 | 2013 | 318 | 0.370 |
Why?
|
| Forecasting | 3 | 2019 | 232 | 0.370 |
Why?
|
| RNA, Messenger | 2 | 2017 | 1530 | 0.370 |
Why?
|
| Cardiomyopathies | 2 | 2014 | 123 | 0.360 |
Why?
|
| Percutaneous Coronary Intervention | 4 | 2019 | 208 | 0.360 |
Why?
|
| Genomics | 5 | 2023 | 369 | 0.360 |
Why?
|
| Coronary Circulation | 1 | 2011 | 52 | 0.360 |
Why?
|
| Ambulatory Care | 4 | 2025 | 310 | 0.360 |
Why?
|
| Severity of Illness Index | 8 | 2020 | 1538 | 0.360 |
Why?
|
| Healthcare Disparities | 3 | 2021 | 355 | 0.360 |
Why?
|
| Coronary Artery Bypass | 5 | 2019 | 297 | 0.360 |
Why?
|
| Resistin | 1 | 2011 | 6 | 0.360 |
Why?
|
| Depression | 5 | 2021 | 890 | 0.350 |
Why?
|
| Adiponectin | 1 | 2011 | 36 | 0.350 |
Why?
|
| Primary Health Care | 8 | 2025 | 686 | 0.340 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2019 | 129 | 0.330 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2011 | 78 | 0.330 |
Why?
|
| Warfarin | 3 | 2020 | 111 | 0.330 |
Why?
|
| Venous Thromboembolism | 3 | 2020 | 148 | 0.330 |
Why?
|
| Gene Expression Regulation | 6 | 2017 | 1596 | 0.320 |
Why?
|
| Albuminuria | 1 | 2009 | 31 | 0.320 |
Why?
|
| Global Health | 3 | 2017 | 182 | 0.320 |
Why?
|
| Sex Distribution | 6 | 2018 | 251 | 0.320 |
Why?
|
| Quality Indicators, Health Care | 4 | 2020 | 337 | 0.320 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 3 | 2019 | 32 | 0.310 |
Why?
|
| India | 3 | 2018 | 157 | 0.310 |
Why?
|
| Religion | 2 | 2019 | 30 | 0.310 |
Why?
|
| Primary Prevention | 3 | 2018 | 136 | 0.310 |
Why?
|
| Health Behavior | 3 | 2024 | 468 | 0.310 |
Why?
|
| Viral Load | 3 | 2025 | 228 | 0.300 |
Why?
|
| Social Support | 3 | 2021 | 371 | 0.300 |
Why?
|
| Antihypertensive Agents | 4 | 2021 | 164 | 0.300 |
Why?
|
| Diastole | 2 | 2020 | 91 | 0.300 |
Why?
|
| Prosthesis Failure | 1 | 2009 | 74 | 0.300 |
Why?
|
| Patient Transfer | 2 | 2020 | 93 | 0.300 |
Why?
|
| Documentation | 2 | 2020 | 128 | 0.300 |
Why?
|
| Homes for the Aged | 2 | 2021 | 161 | 0.290 |
Why?
|
| Perception | 2 | 2022 | 173 | 0.290 |
Why?
|
| Kidney | 2 | 2013 | 441 | 0.290 |
Why?
|
| ROC Curve | 5 | 2020 | 278 | 0.290 |
Why?
|
| Outpatients | 2 | 2025 | 142 | 0.290 |
Why?
|
| ST Elevation Myocardial Infarction | 3 | 2019 | 90 | 0.290 |
Why?
|
| Referral and Consultation | 3 | 2023 | 420 | 0.280 |
Why?
|
| Secondary Prevention | 5 | 2018 | 162 | 0.280 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2020 | 85 | 0.280 |
Why?
|
| Nursing Homes | 4 | 2021 | 667 | 0.280 |
Why?
|
| Patient Participation | 4 | 2023 | 228 | 0.270 |
Why?
|
| Cystatins | 1 | 2007 | 1 | 0.270 |
Why?
|
| False Positive Reactions | 2 | 2024 | 77 | 0.270 |
Why?
|
| Shock, Cardiogenic | 3 | 2017 | 102 | 0.270 |
Why?
|
| Physical Endurance | 1 | 2007 | 48 | 0.260 |
Why?
|
| Neoplasms | 3 | 2025 | 1351 | 0.260 |
Why?
|
| Multiple Chronic Conditions | 2 | 2018 | 39 | 0.260 |
Why?
|
| Activities of Daily Living | 4 | 2021 | 290 | 0.250 |
Why?
|
| Atherosclerosis | 2 | 2020 | 153 | 0.250 |
Why?
|
| Physician-Patient Relations | 2 | 2018 | 419 | 0.250 |
Why?
|
| Survival Analysis | 7 | 2018 | 577 | 0.250 |
Why?
|
| Genome, Human | 2 | 2021 | 237 | 0.240 |
Why?
|
| Delivery of Health Care | 3 | 2024 | 430 | 0.240 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2018 | 152 | 0.240 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2021 | 143 | 0.230 |
Why?
|
| Licensure, Medical | 1 | 2025 | 8 | 0.230 |
Why?
|
| Histone Deacetylases | 1 | 2025 | 65 | 0.230 |
Why?
|
| Continuity of Patient Care | 2 | 2020 | 174 | 0.230 |
Why?
|
| Multifactorial Inheritance | 1 | 2025 | 26 | 0.230 |
Why?
|
| Chi-Square Distribution | 6 | 2017 | 416 | 0.230 |
Why?
|
| Smoking | 5 | 2021 | 864 | 0.220 |
Why?
|
| Metformin | 1 | 2025 | 73 | 0.220 |
Why?
|
| Genetic Markers | 3 | 2020 | 129 | 0.220 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2024 | 10 | 0.220 |
Why?
|
| Myocardial Revascularization | 3 | 2016 | 76 | 0.220 |
Why?
|
| Lysine | 1 | 2024 | 82 | 0.220 |
Why?
|
| Transitional Care | 1 | 2024 | 25 | 0.220 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2021 | 19 | 0.220 |
Why?
|
| Allied Health Personnel | 1 | 2024 | 30 | 0.220 |
Why?
|
| Phenotype | 6 | 2021 | 1192 | 0.220 |
Why?
|
| Immunologic Tests | 1 | 2024 | 5 | 0.220 |
Why?
|
| Disease Progression | 6 | 2016 | 1161 | 0.220 |
Why?
|
| Genetic Drift | 1 | 2024 | 16 | 0.220 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2024 | 117 | 0.210 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2024 | 39 | 0.210 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2024 | 694 | 0.210 |
Why?
|
| Self-Management | 1 | 2024 | 61 | 0.210 |
Why?
|
| Body Weight | 3 | 2019 | 375 | 0.210 |
Why?
|
| Latent Tuberculosis | 1 | 2024 | 23 | 0.210 |
Why?
|
| Gene Expression Profiling | 6 | 2017 | 767 | 0.210 |
Why?
|
| Multimorbidity | 2 | 2020 | 48 | 0.210 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2016 | 226 | 0.210 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2016 | 215 | 0.200 |
Why?
|
| Heart Ventricles | 3 | 2020 | 262 | 0.200 |
Why?
|
| Health Services Accessibility | 2 | 2018 | 559 | 0.200 |
Why?
|
| Educational Measurement | 1 | 2025 | 216 | 0.200 |
Why?
|
| Vision Disorders | 2 | 2022 | 64 | 0.200 |
Why?
|
| Depressive Disorder | 1 | 2005 | 283 | 0.200 |
Why?
|
| Neurospora | 1 | 2022 | 2 | 0.200 |
Why?
|
| Energy Metabolism | 1 | 2025 | 378 | 0.200 |
Why?
|
| Wrist | 2 | 2019 | 39 | 0.200 |
Why?
|
| Creatinine | 4 | 2016 | 136 | 0.190 |
Why?
|
| Aortic Valve Stenosis | 1 | 2025 | 186 | 0.190 |
Why?
|
| Pattern Recognition, Automated | 2 | 2013 | 53 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 5 | 2019 | 731 | 0.190 |
Why?
|
| Databases, Factual | 5 | 2020 | 864 | 0.190 |
Why?
|
| Ecosystem | 1 | 2022 | 52 | 0.190 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2013 | 45 | 0.190 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 165 | 0.190 |
Why?
|
| Epigenesis, Genetic | 1 | 2025 | 384 | 0.190 |
Why?
|
| Protein Biosynthesis | 1 | 2024 | 316 | 0.190 |
Why?
|
| Anxiety Disorders | 1 | 2023 | 191 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 1 | 2023 | 515 | 0.190 |
Why?
|
| Pandemics | 2 | 2024 | 668 | 0.180 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2021 | 9 | 0.180 |
Why?
|
| Confidence Intervals | 5 | 2016 | 239 | 0.180 |
Why?
|
| Ischemic Attack, Transient | 2 | 2019 | 95 | 0.180 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 49 | 0.180 |
Why?
|
| Evolution, Molecular | 1 | 2024 | 322 | 0.180 |
Why?
|
| Software Validation | 1 | 2021 | 9 | 0.180 |
Why?
|
| Nutrition Surveys | 2 | 2022 | 142 | 0.170 |
Why?
|
| Heart Valve Diseases | 2 | 2019 | 95 | 0.170 |
Why?
|
| Animals | 7 | 2025 | 20501 | 0.170 |
Why?
|
| Chest Pain | 1 | 2021 | 84 | 0.170 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 128 | 0.170 |
Why?
|
| International Classification of Diseases | 2 | 2019 | 135 | 0.170 |
Why?
|
| House Calls | 1 | 2020 | 23 | 0.170 |
Why?
|
| Length of Stay | 8 | 2017 | 806 | 0.170 |
Why?
|
| Hospitals, University | 1 | 2020 | 54 | 0.170 |
Why?
|
| Motion | 5 | 2024 | 59 | 0.170 |
Why?
|
| Community Health Services | 2 | 2012 | 128 | 0.170 |
Why?
|
| Life Style | 4 | 2024 | 310 | 0.170 |
Why?
|
| Drug Dosage Calculations | 1 | 2020 | 9 | 0.170 |
Why?
|
| Gene Expression | 2 | 2013 | 831 | 0.170 |
Why?
|
| Validation Studies as Topic | 1 | 2020 | 20 | 0.170 |
Why?
|
| Nurses | 1 | 2021 | 107 | 0.160 |
Why?
|
| Biomedical Research | 3 | 2024 | 267 | 0.160 |
Why?
|
| Tuberculosis | 1 | 2024 | 295 | 0.160 |
Why?
|
| Kidney Diseases | 3 | 2016 | 175 | 0.160 |
Why?
|
| Calcium Channel Blockers | 2 | 2020 | 55 | 0.160 |
Why?
|
| Genetic Loci | 3 | 2017 | 115 | 0.160 |
Why?
|
| Polypharmacy | 1 | 2020 | 61 | 0.160 |
Why?
|
| Drug Interactions | 1 | 2020 | 127 | 0.160 |
Why?
|
| Precision Medicine | 1 | 2021 | 118 | 0.160 |
Why?
|
| Walking Speed | 1 | 2019 | 21 | 0.160 |
Why?
|
| Ceramides | 1 | 2019 | 25 | 0.160 |
Why?
|
| Suburban Population | 1 | 2019 | 9 | 0.160 |
Why?
|
| Religion and Medicine | 1 | 2019 | 19 | 0.160 |
Why?
|
| Aortic Diseases | 1 | 2020 | 74 | 0.160 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 155 | 0.160 |
Why?
|
| Physician Assistants | 1 | 2019 | 36 | 0.160 |
Why?
|
| Databases, Genetic | 2 | 2017 | 89 | 0.150 |
Why?
|
| Patient Selection | 2 | 2020 | 488 | 0.150 |
Why?
|
| Proteomics | 2 | 2019 | 280 | 0.150 |
Why?
|
| Office Visits | 1 | 2019 | 48 | 0.150 |
Why?
|
| Entropy | 3 | 2019 | 23 | 0.150 |
Why?
|
| Diuretics | 2 | 2016 | 56 | 0.150 |
Why?
|
| Blood Proteins | 1 | 2019 | 76 | 0.150 |
Why?
|
| Rivaroxaban | 1 | 2018 | 19 | 0.150 |
Why?
|
| Heart Valves | 1 | 2018 | 26 | 0.150 |
Why?
|
| Dabigatran | 1 | 2018 | 20 | 0.150 |
Why?
|
| Meta-Analysis as Topic | 2 | 2016 | 76 | 0.150 |
Why?
|
| Economics | 1 | 2018 | 7 | 0.150 |
Why?
|
| Metabolomics | 2 | 2016 | 53 | 0.150 |
Why?
|
| Genetic Association Studies | 2 | 2016 | 120 | 0.150 |
Why?
|
| Young Adult | 7 | 2024 | 4669 | 0.150 |
Why?
|
| Urban Population | 1 | 2019 | 191 | 0.150 |
Why?
|
| Drosophila melanogaster | 1 | 2022 | 493 | 0.140 |
Why?
|
| Nurse Practitioners | 1 | 2019 | 116 | 0.140 |
Why?
|
| Insulin Resistance | 2 | 2012 | 410 | 0.140 |
Why?
|
| Equipment Design | 2 | 2025 | 347 | 0.140 |
Why?
|
| Information Seeking Behavior | 1 | 2018 | 38 | 0.140 |
Why?
|
| Adenocarcinoma | 2 | 2015 | 340 | 0.140 |
Why?
|
| Thrombolytic Therapy | 1 | 2019 | 190 | 0.140 |
Why?
|
| Monitoring, Ambulatory | 1 | 2018 | 57 | 0.140 |
Why?
|
| Telomere Homeostasis | 1 | 2017 | 4 | 0.140 |
Why?
|
| Trisomy | 2 | 2013 | 21 | 0.140 |
Why?
|
| Drug Overdose | 1 | 2020 | 130 | 0.140 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 72 | 0.140 |
Why?
|
| Hypotension, Orthostatic | 1 | 2017 | 27 | 0.140 |
Why?
|
| Communication Barriers | 1 | 2018 | 67 | 0.140 |
Why?
|
| Professional-Family Relations | 1 | 2018 | 87 | 0.140 |
Why?
|
| Transportation of Patients | 1 | 2018 | 47 | 0.140 |
Why?
|
| Diet | 1 | 2021 | 520 | 0.140 |
Why?
|
| Telomere | 1 | 2017 | 52 | 0.140 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 252 | 0.140 |
Why?
|
| Data Collection | 2 | 2022 | 383 | 0.140 |
Why?
|
| Attitude to Health | 2 | 2018 | 288 | 0.130 |
Why?
|
| Leukocytes | 1 | 2017 | 103 | 0.130 |
Why?
|
| Patient Safety | 1 | 2020 | 242 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 3366 | 0.130 |
Why?
|
| Linear Models | 3 | 2015 | 408 | 0.130 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2018 | 359 | 0.130 |
Why?
|
| Blood Glucose | 2 | 2021 | 479 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 3 | 2024 | 309 | 0.130 |
Why?
|
| Home Nursing | 1 | 2016 | 21 | 0.130 |
Why?
|
| International Cooperation | 1 | 2017 | 89 | 0.130 |
Why?
|
| Europe | 5 | 2016 | 194 | 0.130 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2016 | 35 | 0.130 |
Why?
|
| Regression Analysis | 1 | 2017 | 495 | 0.130 |
Why?
|
| Cardiomegaly | 1 | 2016 | 33 | 0.130 |
Why?
|
| Quality of Health Care | 1 | 2020 | 515 | 0.130 |
Why?
|
| Health Services | 1 | 2017 | 80 | 0.130 |
Why?
|
| Blood Flow Velocity | 1 | 2016 | 71 | 0.130 |
Why?
|
| Manometry | 1 | 2016 | 29 | 0.130 |
Why?
|
| Area Under Curve | 1 | 2016 | 146 | 0.130 |
Why?
|
| Mitoxantrone | 1 | 2016 | 16 | 0.130 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2016 | 26 | 0.120 |
Why?
|
| Psychosocial Deprivation | 1 | 2015 | 8 | 0.120 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 45 | 0.120 |
Why?
|
| White Matter | 1 | 2017 | 123 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 966 | 0.120 |
Why?
|
| Attitude to Computers | 1 | 2015 | 21 | 0.120 |
Why?
|
| Lung Diseases | 1 | 2017 | 179 | 0.120 |
Why?
|
| Preoperative Period | 1 | 2015 | 71 | 0.120 |
Why?
|
| Cryosurgery | 1 | 2015 | 28 | 0.120 |
Why?
|
| Cerebral Infarction | 1 | 2016 | 82 | 0.120 |
Why?
|
| Hypolipidemic Agents | 1 | 2015 | 25 | 0.120 |
Why?
|
| Critical Care | 1 | 2019 | 397 | 0.120 |
Why?
|
| Exercise Test | 3 | 2025 | 250 | 0.120 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 153 | 0.120 |
Why?
|
| Caregivers | 1 | 2018 | 270 | 0.120 |
Why?
|
| Homeodomain Proteins | 2 | 2014 | 266 | 0.120 |
Why?
|
| Arginine | 1 | 2016 | 124 | 0.120 |
Why?
|
| Endothelium, Vascular | 1 | 2016 | 173 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 595 | 0.120 |
Why?
|
| Ileal Neoplasms | 1 | 2015 | 3 | 0.120 |
Why?
|
| Acute Disease | 5 | 2014 | 669 | 0.110 |
Why?
|
| Cause of Death | 4 | 2019 | 220 | 0.110 |
Why?
|
| Urinary Diversion | 1 | 2015 | 12 | 0.110 |
Why?
|
| DNA Methylation | 1 | 2017 | 290 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 760 | 0.110 |
Why?
|
| Internet | 1 | 2018 | 466 | 0.110 |
Why?
|
| Program Evaluation | 1 | 2017 | 485 | 0.110 |
Why?
|
| Mice | 3 | 2025 | 10751 | 0.110 |
Why?
|
| Neuroimaging | 1 | 2016 | 152 | 0.110 |
Why?
|
| Myocytes, Cardiac | 2 | 2025 | 96 | 0.110 |
Why?
|
| Dyslipidemias | 1 | 2014 | 36 | 0.110 |
Why?
|
| Memory Disorders | 1 | 2014 | 50 | 0.110 |
Why?
|
| Galectin 3 | 1 | 2014 | 7 | 0.110 |
Why?
|
| Clinical Trials as Topic | 3 | 2021 | 455 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2014 | 17 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 129 | 0.110 |
Why?
|
| Executive Function | 1 | 2014 | 65 | 0.110 |
Why?
|
| Students, Medical | 1 | 2017 | 261 | 0.110 |
Why?
|
| Hyperglycemia | 1 | 2014 | 104 | 0.110 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2013 | 4 | 0.110 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2013 | 15 | 0.110 |
Why?
|
| Critical Illness | 3 | 2022 | 322 | 0.110 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2013 | 8 | 0.100 |
Why?
|
| Lipids | 1 | 2016 | 312 | 0.100 |
Why?
|
| Psychomotor Performance | 1 | 2014 | 137 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 192 | 0.100 |
Why?
|
| Communication | 1 | 2018 | 570 | 0.100 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2013 | 15 | 0.100 |
Why?
|
| Medication Adherence | 3 | 2022 | 202 | 0.100 |
Why?
|
| Dronabinol | 1 | 2013 | 32 | 0.100 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2011 | 168 | 0.100 |
Why?
|
| Digestive System Diseases | 1 | 2013 | 14 | 0.100 |
Why?
|
| Triglycerides | 1 | 2014 | 244 | 0.100 |
Why?
|
| Leukoencephalopathies | 1 | 2013 | 25 | 0.100 |
Why?
|
| Muscle Proteins | 1 | 2013 | 116 | 0.100 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 1092 | 0.100 |
Why?
|
| Cardiotonic Agents | 1 | 2013 | 51 | 0.100 |
Why?
|
| alpha-2-HS-Glycoprotein | 1 | 2012 | 2 | 0.100 |
Why?
|
| Retinol-Binding Proteins, Plasma | 1 | 2012 | 4 | 0.100 |
Why?
|
| Emergency Medical Services | 1 | 2016 | 263 | 0.100 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2012 | 22 | 0.100 |
Why?
|
| Cross-Over Studies | 1 | 2013 | 161 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 2013 | 104 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 2154 | 0.100 |
Why?
|
| Chronic Disease | 3 | 2017 | 750 | 0.100 |
Why?
|
| Support Vector Machine | 2 | 2023 | 23 | 0.100 |
Why?
|
| Saliva | 2 | 2024 | 103 | 0.100 |
Why?
|
| Peptide Fragments | 1 | 2014 | 408 | 0.100 |
Why?
|
| Antigens, Viral | 2 | 2024 | 132 | 0.100 |
Why?
|
| Central Nervous System Stimulants | 1 | 2012 | 65 | 0.090 |
Why?
|
| Heart | 2 | 2020 | 281 | 0.090 |
Why?
|
| Heart Function Tests | 1 | 2011 | 15 | 0.090 |
Why?
|
| Cardiac Output | 1 | 2011 | 28 | 0.090 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 427 | 0.090 |
Why?
|
| Molecular Biology | 1 | 2011 | 66 | 0.090 |
Why?
|
| Metabolic Syndrome | 1 | 2012 | 142 | 0.090 |
Why?
|
| Ultrasonography | 2 | 2014 | 480 | 0.090 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2012 | 159 | 0.090 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2011 | 32 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 420 | 0.090 |
Why?
|
| Age Distribution | 3 | 2016 | 257 | 0.090 |
Why?
|
| Coronary Stenosis | 1 | 2011 | 39 | 0.090 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2013 | 124 | 0.080 |
Why?
|
| Pedigree | 1 | 2011 | 193 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2012 | 305 | 0.080 |
Why?
|
| Decision Making | 1 | 2014 | 404 | 0.080 |
Why?
|
| Mental Status and Dementia Tests | 2 | 2020 | 19 | 0.080 |
Why?
|
| Brain | 3 | 2017 | 1544 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 14 | 2 | 2013 | 17 | 0.080 |
Why?
|
| Accelerometry | 2 | 2021 | 63 | 0.080 |
Why?
|
| RNA | 1 | 2013 | 423 | 0.080 |
Why?
|
| Organ Size | 1 | 2010 | 172 | 0.080 |
Why?
|
| Heart Conduction System | 1 | 2009 | 54 | 0.080 |
Why?
|
| Self Care | 2 | 2024 | 210 | 0.080 |
Why?
|
| Educational Status | 2 | 2023 | 275 | 0.080 |
Why?
|
| Health Status | 2 | 2017 | 435 | 0.080 |
Why?
|
| Electricity | 1 | 2009 | 8 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2013 | 702 | 0.080 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2009 | 37 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2013 | 476 | 0.070 |
Why?
|
| California | 1 | 2008 | 174 | 0.070 |
Why?
|
| Morbidity | 2 | 2019 | 113 | 0.070 |
Why?
|
| American Heart Association | 2 | 2020 | 126 | 0.070 |
Why?
|
| Comparative Effectiveness Research | 2 | 2020 | 46 | 0.070 |
Why?
|
| Microcomputers | 2 | 2020 | 7 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 147 | 0.070 |
Why?
|
| Cystatin C | 1 | 2007 | 9 | 0.070 |
Why?
|
| Crack Cocaine | 1 | 2007 | 7 | 0.070 |
Why?
|
| Skilled Nursing Facilities | 2 | 2018 | 80 | 0.070 |
Why?
|
| Barrett Esophagus | 1 | 2006 | 30 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2019 | 369 | 0.060 |
Why?
|
| Esophagus | 1 | 2006 | 50 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2008 | 359 | 0.060 |
Why?
|
| Acetylation | 1 | 2025 | 121 | 0.060 |
Why?
|
| Cholesterol, HDL | 2 | 2016 | 72 | 0.060 |
Why?
|
| Mental Disorders | 1 | 2013 | 784 | 0.060 |
Why?
|
| Esophageal Neoplasms | 1 | 2006 | 83 | 0.060 |
Why?
|
| Cholesterol, LDL | 2 | 2016 | 102 | 0.060 |
Why?
|
| Health Services Research | 2 | 2019 | 268 | 0.060 |
Why?
|
| Social Class | 1 | 2005 | 131 | 0.060 |
Why?
|
| Coronary Angiography | 2 | 2019 | 201 | 0.060 |
Why?
|
| Extracellular Matrix | 1 | 2025 | 139 | 0.060 |
Why?
|
| Abdominal Pain | 1 | 2005 | 102 | 0.060 |
Why?
|
| Mosaicism | 1 | 2004 | 30 | 0.060 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2024 | 24 | 0.060 |
Why?
|
| Drug Prescriptions | 2 | 2019 | 168 | 0.050 |
Why?
|
| Oximetry | 2 | 2014 | 48 | 0.050 |
Why?
|
| Neuropsychological Tests | 2 | 2017 | 392 | 0.050 |
Why?
|
| Aspirin | 2 | 2016 | 171 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 776 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2006 | 303 | 0.050 |
Why?
|
| Censuses | 1 | 2023 | 17 | 0.050 |
Why?
|
| Nose | 1 | 2024 | 31 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2025 | 386 | 0.050 |
Why?
|
| Aortic Valve | 1 | 2025 | 190 | 0.050 |
Why?
|
| GABA Plasma Membrane Transport Proteins | 1 | 2023 | 5 | 0.050 |
Why?
|
| Self Efficacy | 1 | 2024 | 201 | 0.050 |
Why?
|
| Systems Biology | 2 | 2015 | 33 | 0.050 |
Why?
|
| Attitude | 1 | 2023 | 99 | 0.050 |
Why?
|
| Health Expenditures | 1 | 2024 | 121 | 0.050 |
Why?
|
| Text Messaging | 1 | 2024 | 84 | 0.050 |
Why?
|
| Behavior Therapy | 1 | 2024 | 167 | 0.050 |
Why?
|
| Focus Groups | 1 | 2024 | 303 | 0.050 |
Why?
|
| Homeostasis | 1 | 2025 | 369 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2023 | 262 | 0.050 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2023 | 75 | 0.050 |
Why?
|
| Medication Errors | 1 | 2023 | 108 | 0.050 |
Why?
|
| Biological Transport | 1 | 2023 | 290 | 0.050 |
Why?
|
| Virus Shedding | 1 | 2022 | 20 | 0.050 |
Why?
|
| South America | 2 | 2013 | 25 | 0.050 |
Why?
|
| New Zealand | 2 | 2013 | 43 | 0.050 |
Why?
|
| Histones | 1 | 2025 | 479 | 0.050 |
Why?
|
| Mitochondria | 1 | 2025 | 361 | 0.050 |
Why?
|
| North America | 2 | 2013 | 111 | 0.050 |
Why?
|
| Australia | 2 | 2013 | 120 | 0.050 |
Why?
|
| Wavelet Analysis | 1 | 2021 | 5 | 0.050 |
Why?
|
| Mammals | 1 | 2023 | 216 | 0.050 |
Why?
|
| Vero Cells | 1 | 2021 | 78 | 0.050 |
Why?
|
| Health Status Disparities | 1 | 2023 | 145 | 0.040 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2021 | 7 | 0.040 |
Why?
|
| Population Density | 1 | 2021 | 14 | 0.040 |
Why?
|
| INDEL Mutation | 1 | 2021 | 19 | 0.040 |
Why?
|
| Adult Children | 1 | 2020 | 6 | 0.040 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 23 | 0.040 |
Why?
|
| Confidentiality | 1 | 2021 | 52 | 0.040 |
Why?
|
| Sample Size | 1 | 2021 | 65 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 206 | 0.040 |
Why?
|
| Digoxin | 1 | 2020 | 21 | 0.040 |
Why?
|
| Quality Control | 1 | 2021 | 74 | 0.040 |
Why?
|
| Automation | 1 | 2020 | 54 | 0.040 |
Why?
|
| Amiodarone | 1 | 2020 | 20 | 0.040 |
Why?
|
| Haplotypes | 1 | 2021 | 130 | 0.040 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2020 | 36 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 81 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2021 | 132 | 0.040 |
Why?
|
| Education | 1 | 2021 | 68 | 0.040 |
Why?
|
| Heterozygote | 1 | 2021 | 169 | 0.040 |
Why?
|
| Natural Language Processing | 1 | 2021 | 48 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2025 | 2092 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2000 | 17 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2021 | 124 | 0.040 |
Why?
|
| Gene Duplication | 1 | 2000 | 34 | 0.040 |
Why?
|
| Medical Records | 2 | 2013 | 137 | 0.040 |
Why?
|
| Triage | 1 | 2021 | 129 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2021 | 339 | 0.040 |
Why?
|
| Chromatin | 1 | 2025 | 604 | 0.040 |
Why?
|
| Overweight | 2 | 2013 | 249 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 148 | 0.040 |
Why?
|
| Cholesterol | 1 | 2021 | 258 | 0.040 |
Why?
|
| Patient Health Questionnaire | 1 | 2019 | 6 | 0.040 |
Why?
|
| Blood Coagulation | 1 | 2020 | 39 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2000 | 65 | 0.040 |
Why?
|
| Databases as Topic | 1 | 2019 | 55 | 0.040 |
Why?
|
| Organ Dysfunction Scores | 1 | 2019 | 23 | 0.040 |
Why?
|
| Mobility Limitation | 1 | 2020 | 49 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2019 | 33 | 0.040 |
Why?
|
| Knowledge | 1 | 2019 | 31 | 0.040 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2019 | 18 | 0.040 |
Why?
|
| Body Height | 1 | 2019 | 67 | 0.040 |
Why?
|
| Language | 1 | 2021 | 150 | 0.040 |
Why?
|
| Noise | 1 | 2019 | 33 | 0.040 |
Why?
|
| Spirituality | 1 | 2019 | 39 | 0.040 |
Why?
|
| Genes, Dominant | 1 | 1999 | 57 | 0.040 |
Why?
|
| Hypothyroidism | 1 | 2019 | 43 | 0.040 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1999 | 41 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2019 | 42 | 0.040 |
Why?
|
| Self Concept | 1 | 2019 | 111 | 0.040 |
Why?
|
| Home Care Services | 1 | 2020 | 98 | 0.040 |
Why?
|
| Boston | 1 | 2019 | 251 | 0.040 |
Why?
|
| Affect | 1 | 2019 | 125 | 0.040 |
Why?
|
| Arabidopsis | 1 | 1999 | 83 | 0.040 |
Why?
|
| Accidental Falls | 1 | 2020 | 124 | 0.040 |
Why?
|
| Adolescent | 2 | 2024 | 6219 | 0.040 |
Why?
|
| Publication Bias | 1 | 2018 | 19 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 97 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 191 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2025 | 2167 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2018 | 74 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 286 | 0.040 |
Why?
|
| Consumer Health Information | 1 | 2018 | 37 | 0.040 |
Why?
|
| Blotting, Southern | 1 | 2017 | 54 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2017 | 37 | 0.040 |
Why?
|
| Abnormalities, Multiple | 2 | 2013 | 55 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2019 | 265 | 0.030 |
Why?
|
| Community-Based Participatory Research | 1 | 2017 | 49 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2017 | 21 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2018 | 216 | 0.030 |
Why?
|
| Peripheral Arterial Disease | 1 | 2019 | 172 | 0.030 |
Why?
|
| Capacity Building | 1 | 2017 | 21 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 240 | 0.030 |
Why?
|
| Pregnancy | 1 | 2024 | 2324 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 143 | 0.030 |
Why?
|
| Marital Status | 1 | 2016 | 45 | 0.030 |
Why?
|
| Health Surveys | 1 | 2018 | 313 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2016 | 46 | 0.030 |
Why?
|
| Hospitals | 1 | 2019 | 388 | 0.030 |
Why?
|
| Genetic Pleiotropy | 1 | 2016 | 3 | 0.030 |
Why?
|
| Causality | 1 | 2016 | 58 | 0.030 |
Why?
|
| Mentors | 1 | 2017 | 119 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2016 | 102 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2016 | 131 | 0.030 |
Why?
|
| Schools, Medical | 1 | 2017 | 145 | 0.030 |
Why?
|
| Age of Onset | 1 | 2016 | 174 | 0.030 |
Why?
|
| Resuscitation Orders | 1 | 2016 | 48 | 0.030 |
Why?
|
| Health Literacy | 1 | 2016 | 85 | 0.030 |
Why?
|
| Platelet Function Tests | 1 | 2015 | 11 | 0.030 |
Why?
|
| CpG Islands | 1 | 2017 | 216 | 0.030 |
Why?
|
| Platelet Aggregation | 1 | 2015 | 24 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2017 | 258 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 374 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2016 | 112 | 0.030 |
Why?
|
| Platelet Activation | 1 | 2015 | 27 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2016 | 147 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 218 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 542 | 0.030 |
Why?
|
| Thyrotoxicosis | 1 | 2015 | 7 | 0.030 |
Why?
|
| Alcoholic Intoxication | 1 | 2015 | 27 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 299 | 0.030 |
Why?
|
| Leadership | 1 | 2017 | 206 | 0.030 |
Why?
|
| Medical Records, Problem-Oriented | 1 | 2014 | 13 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2014 | 78 | 0.030 |
Why?
|
| Physical Examination | 1 | 1995 | 111 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1999 | 557 | 0.030 |
Why?
|
| Uncertainty | 1 | 2014 | 37 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 458 | 0.030 |
Why?
|
| Canada | 1 | 2014 | 153 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 174 | 0.030 |
Why?
|
| Demography | 1 | 2014 | 173 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2014 | 42 | 0.030 |
Why?
|
| Japan | 1 | 2014 | 59 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2016 | 296 | 0.030 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2013 | 7 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2013 | 46 | 0.030 |
Why?
|
| Drug Design | 1 | 2014 | 135 | 0.030 |
Why?
|
| Epidemiologic Research Design | 1 | 2013 | 3 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 295 | 0.030 |
Why?
|
| Fibrosis | 1 | 2014 | 160 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2013 | 45 | 0.030 |
Why?
|
| Heart Murmurs | 1 | 2013 | 5 | 0.030 |
Why?
|
| Iceland | 1 | 2013 | 8 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2013 | 19 | 0.030 |
Why?
|
| Netherlands | 1 | 2013 | 23 | 0.030 |
Why?
|
| Proteinuria | 1 | 2013 | 41 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2013 | 164 | 0.030 |
Why?
|
| History, Ancient | 1 | 2013 | 12 | 0.030 |
Why?
|
| Infant | 2 | 2013 | 1640 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2014 | 288 | 0.020 |
Why?
|
| Patient Admission | 1 | 2014 | 194 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 449 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 317 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2015 | 172 | 0.020 |
Why?
|
| Family Practice | 1 | 1995 | 211 | 0.020 |
Why?
|
| Chromosome Banding | 2 | 2004 | 13 | 0.020 |
Why?
|
| Self-Injurious Behavior | 1 | 2013 | 47 | 0.020 |
Why?
|
| Karyotyping | 2 | 2004 | 48 | 0.020 |
Why?
|
| Tachycardia | 1 | 2012 | 29 | 0.020 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 111 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 66 | 0.020 |
Why?
|
| Computer Systems | 1 | 2011 | 14 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 89 | 0.020 |
Why?
|
| Adiposity | 1 | 2012 | 82 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2004 | 166 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 197 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2013 | 219 | 0.020 |
Why?
|
| Developmental Disabilities | 1 | 2013 | 114 | 0.020 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2011 | 51 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 664 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 734 | 0.020 |
Why?
|
| Thinness | 1 | 2011 | 44 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2013 | 509 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 607 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 546 | 0.020 |
Why?
|
| Fourier Analysis | 1 | 2011 | 32 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2012 | 203 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 662 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 684 | 0.020 |
Why?
|
| Echocardiography, Stress | 1 | 2009 | 14 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 873 | 0.020 |
Why?
|
| Systole | 1 | 2009 | 108 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2011 | 268 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2015 | 1298 | 0.020 |
Why?
|
| San Francisco | 1 | 2007 | 11 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2006 | 17 | 0.020 |
Why?
|
| Metaplasia | 1 | 2006 | 18 | 0.020 |
Why?
|
| Editorial Policies | 1 | 2007 | 54 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 75 | 0.020 |
Why?
|
| beta Catenin | 1 | 2006 | 96 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2014 | 1502 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 1995 | 1189 | 0.020 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2007 | 90 | 0.010 |
Why?
|
| Bronchopneumonia | 1 | 2004 | 1 | 0.010 |
Why?
|
| Ring Chromosomes | 1 | 2004 | 2 | 0.010 |
Why?
|
| Coloboma | 1 | 2004 | 2 | 0.010 |
Why?
|
| Facies | 1 | 2004 | 9 | 0.010 |
Why?
|
| Cytogenetics | 1 | 2004 | 9 | 0.010 |
Why?
|
| Biopsy | 1 | 2006 | 441 | 0.010 |
Why?
|
| Microcephaly | 1 | 2004 | 14 | 0.010 |
Why?
|
| Periodicals as Topic | 1 | 2007 | 172 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2004 | 124 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 3014 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 886 | 0.010 |
Why?
|
| Retina | 1 | 2004 | 124 | 0.010 |
Why?
|
| Child | 1 | 2013 | 4502 | 0.010 |
Why?
|
| Seizures | 1 | 2004 | 143 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2004 | 303 | 0.010 |
Why?
|
| Chromosome Disorders | 1 | 2000 | 14 | 0.010 |
Why?
|
| Protein Phosphatase 2 | 1 | 1999 | 10 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 1999 | 62 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1999 | 245 | 0.010 |
Why?
|
| DNA Primers | 1 | 1999 | 289 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2004 | 1980 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1999 | 361 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1999 | 375 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 1999 | 199 | 0.010 |
Why?
|
| Alleles | 1 | 1999 | 446 | 0.010 |
Why?
|
| Base Sequence | 1 | 1999 | 1322 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1999 | 1583 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1999 | 1980 | 0.010 |
Why?
|
| Patient Simulation | 1 | 1995 | 71 | 0.010 |
Why?
|
| Clinical Competence | 1 | 1995 | 723 | 0.000 |
Why?
|